Overview
Safety and Efficacy Study of CLS001Topical Gel Compared to Vehicle in Subjects With Inflammatory Acne Vulgaris
Status:
Completed
Completed
Trial end date:
1969-12-31
1969-12-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
The primary objective of this study is to evaluate the safety and efficacy of once-daily topical application of CLS001 1%, 1.75% and 2.5% topical gel compared to vehicle topical gel in subjects with inflammatory acne vulgarisPhase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Cutanea Life Sciences, Inc.
Maruho Co., Ltd.
Criteria
Inclusion Criteria:- Male or non-pregnant female subjects with facial acne vulgaris, 12 years of age or
older.
- Subjects with ≥20 inflammatory facial lesions (papules, pustules) inclusive of the
nose, with a maximum of 9 inflammatory pustules.
- An Investigator's Global Assessment (IGA) of Moderate (3) or Severe (4)
Exclusion Criteria:
- Subjects with acne conglobate, acne fulminans, and secondary acne (chloracne,
drug-induced acne, polycystic ovarian syndrome, etc.)
- Subjects with greater that 75 facial non-inflammatory lesions (open and/or closed
comedones; excluding the nose)
- Subjects with more than 2 facial nodulocystic lesions